Literature DB >> 1940949

The muscle findings in the neuroleptic malignant syndrome associated with lysergic acid diethylamide.

W M Behan1, A M Bakheit, P O Behan, I A More.   

Abstract

A detailed pathological description of the muscle findings in a case of the neuroleptic malignant syndrome (NMS) following ingestion of lysergic acid diethylamide (LSD) is given, including the first ultrastructural analysis. Focal necrosis, oedema, and hypercontraction of fibres with glycogen and lipid depletion, were identified, all of which had resolved completely a year later. The findings are compared with those in malignant hyperthermia. It is suggested that the results support the view that in NMS, the muscle rigidity is due to central mechanisms and, in both this disorder and malignant hyperthermia, it is responsible for the hyperpyrexia and its life-threatening complications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940949      PMCID: PMC1014484          DOI: 10.1136/jnnp.54.8.741

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Ultrastructural changes of muscle in malignant hyperthermia.

Authors:  H H Schiller; W G Mair
Journal:  J Neurol Sci       Date:  1974-01       Impact factor: 3.181

2.  Dantrolene, a direct acting skeletal muscle relaxant.

Authors:  K O Ellis; A W Castellion; L J Honkomp; F L Wessels; J E Carpenter; R P Halliday
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

3.  Malignant hyperthermia in pigs: calcium ion uptake by mitochondria from skeletal muscle of susceptible animals given neuroleptic drugs and halothane.

Authors:  C J Somers; J V McLoughlin
Journal:  J Comp Pathol       Date:  1982-04       Impact factor: 1.311

4.  Neuroleptic malignant syndrome. Successful treatment with bromocriptine.

Authors:  P S Mueller; J W Vester; J Fermaglich
Journal:  JAMA       Date:  1983-01-21       Impact factor: 56.272

Review 5.  The neuroleptic malignant syndrome--a review.

Authors:  W R Gibb; A J Lees
Journal:  Q J Med       Date:  1985-08

6.  Malignant hyperthermia susceptibility in neuroleptic malignant syndrome.

Authors:  S N Caroff; H Rosenberg; J E Fletcher; T D Heiman-Patterson; S C Mann
Journal:  Anesthesiology       Date:  1987-07       Impact factor: 7.892

7.  Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.

Authors:  M Goulon; P de Rohan-Chabot; D Elkharrat; P Gajdos; C Bismuth; F Conso
Journal:  Neurology       Date:  1983-04       Impact factor: 9.910

Review 8.  Malignant hyperthermia.

Authors:  G A Gronert
Journal:  Anesthesiology       Date:  1980-11       Impact factor: 7.892

9.  Laboratory testing on cerebrospinal fluid. A reappraisal.

Authors:  R A Hayward; M F Shapiro; R K Oye
Journal:  Lancet       Date:  1987-01-03       Impact factor: 79.321

10.  The neuroleptic syndrome and central dopamine metabolites.

Authors:  G D Tollefson; M J Garvey
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

View more
  4 in total

1.  Muscle changes in the neuroleptic malignant syndrome.

Authors:  W M Behan; M Madigan; B J Clark; J Goldberg; D R McLellan
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

3.  Lack of prophylactic or therapeutic efficacy of 5-HT2A receptor antagonists in halothane-induced porcine malignant hyperthermia.

Authors:  W Löscher; C Gerdes; A Richter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

Review 4.  d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

Authors:  Danilo De Gregorio; Stefano Comai; Luca Posa; Gabriella Gobbi
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.